A direct-indirect dual-layer flat-panel detector for breast cancer detection
Active Project Grant Awarded Last action
- Award ID
- R01EB035551
- Recipient
-
The Research Foundation For The State University Of New York UEI M746VC6XMNH9 Part of The Research Foundation For The State University Of New York
- Awarding agency
-
National Institute of Biomedical Imaging and Bioenginering
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,198,320
Award facts
- Assistance listing
- 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health
- Completion date 64% complete
- Place of performance
- Stony Brook, NY 11794, USA
Award details come from USAspending.gov.
Description
- Abstract
- The goal of the proposed work is to develop a novel dual-layer flat-panel detector (dlfpd) based on mature energy-integrating detector technology and translate IT clinically for dual- energy spectral digital breast tomosynthesis (DE-DBT). This will improve the outcome of breast cancer screening, diagnosis and treatment monitoring. Our objectives are two folds: 1. Develop a dlfpd to allow rapid clinical translation of spectral breast imaging without patient motion artifact. 2. Develop spectral imaging techniques based on dlfpd and establish its clinical feasibility using patient studies. Our objectives will be accomplished through the following three specific aims: (1) design, optimize and fabricate a prototype dlfpd for spectral breast imaging. Aim 1 will lead to the development and clinical translation of dlfpd that acquires two mammograms at different energies using a single exposure, allowing perfectly registered spectral images without artifacts due to patient motion. (2) develop dlfpd based DE-DBT techniques using simulation methods. Aim 2 will lead to the development of spectral image processing techniques for dlfpd based systems with and without iodinated contrast agent. (3) integrate the prototype dlfpd with a clinical DBT system and investigate DE-DBT performance through phantom and patient imaging studies. Aim 3 will translate the dlfpd and DE-DBT techniques developed in aims 1 and 2 into clinical reality. The outcomes of the proposed work are: 1. Advancement in dlfpd hardware that permit rapid clinical translation; 2. Development of a variety of dlfpd based DE-DBT techniques, with and without iodinated contrast agent; 3. Clinical evaluation of the feasibility of DE-DBT for breast cancer detection.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $553,492 | |
| Amendment | $500,622 | |
| Amendment | $572,103 | |
| Original award | $572,103 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Siemens Medical Solutions Usa, Inc. | $61,253 | |
| Siemens Medical Solutions Usa, Inc. | $25,600 | |
| Siemens Medical Solutions Usa, Inc. | $56,210 | |
| Analogic Corp | $41,417 | |
| Siemens Medical Solutions Usa, Inc. | $57,197 | |
| Siemens Medical Solutions Usa, Inc. | $57,197 |
Quick answers
Who received award R01EB035551?
R01EB035551 was awarded to The Research Foundation For The State University Of New York by National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health) on June 1, 2024.
How much is award R01EB035551 worth?
$2,198,320 has been obligated on R01EB035551.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award